Trial · NCT00083174
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Women With Serious Adverse Events | Open-label Extension: Exemestane | 0.0 | 95% Confidence Interval 0.0 to 0.5 | percentage of women | |
| Invasive Breast Cancer Incidence (Breast Cancer-Free Survival) | Randomization Period: Exemestane | 0.19 | 95% Confidence Interval 0.08 to 0.30 | percentage of cases/follow-up person-yr | |
| Invasive Breast Cancer Incidence (Breast Cancer-Free Survival) | Randomization Period: Placebo | 0.55 | 95% Confidence Interval 0.36 to 0.73 | percentage of cases/follow-up person-yr | |
| Total Incidence of Invasive and Non-invasive (DCIS) Breast Cancer | Randomization Period: Exemestane | 0.35 | 95% Confidence Interval 0.20 to 0.50 | percentage of cases/follow-up person-yr | |
| Total Incidence of Invasive and Non-invasive (DCIS) Breast Cancer | Randomization Period: Placebo | 0.77 | 95% Confidence Interval 0.54 to 0.99 | percentage of cases/follow-up person-yr | |
| Incidence of Lobular Carcinoma in Situ, Atypical Ductal Hyperplasia and Atypical Lobular Hyperplasia Events | Randomization Period: Exemestane | 0.07 | 95% Confidence Interval 0.00 to 0.15 | percentage of cases/follow-up person-yr | |
| Incidence of Lobular Carcinoma in Situ, Atypical Ductal Hyperplasia and Atypical Lobular Hyperplasia Events | Randomization Period: Placebo | 0.20 | 95% Confidence Interval 0.08 to 0.32 | percentage of cases/follow-up person-yr | |
| Number of Clinical Breast Biopsies | Randomization Period: Exemestane | 1 | Full Range 1 to 3 | number of clinical breast biopsies | |
| Number of Clinical Breast Biopsies | Randomization Period: Placebo | 1 | Full Range 1 to 3 | number of clinical breast biopsies | |
| Incidence of All Clinical Fractures | Randomization Period: Exemestane | 149 | participants | ||
| Incidence of All Clinical Fractures | Randomization Period: Placebo | 143 | participants | ||
| Incidence of Clinically Relevant Cardiac Events | Randomization Period: Exemestane | 106 | participants | ||
| Incidence of Clinically Relevant Cardiac Events | Randomization Period: Placebo | 111 | participants | ||
| Incidences of Other Malignancies | Randomization Period: Exemestane | 50 | participants | ||
| Incidences of Other Malignancies | Randomization Period: Placebo | 42 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00083174/results